DigestRedComo funciona
Red
/
Empresas
Sp
No verificado

Spruce Biosciences, Inc.

Sobre qué escribimos

BiotecnologíaFarmacéuticaMedicina - VariosSaludWeb y redes sociales

19 Comunicados de prensa

Ver todos los comunicados de prensa
08/01/2026
Biotecnología
Farmacéutica
Salud
Spruce Biosciences Secures Up to $50 Million in Growth Capital from Avenue Capital
Fuente
Spruce Biosciences, Inc.
Editor
Business Wire
1.00
0
15/12/2025
Mercado laboral
Biotecnología
Farmacéutica
Salud
Spruce Biosciences Appoints Proven Pharmaceutical Commercial Leader Keli Walbert to Board of Directors
Fuente
Spruce Biosciences, Inc.
Editor
Business Wire
1.00
0
10/11/2025
Mercado de valores
Salud
Medicina - Varios
Ciencia
Farmacéutica
Biotecnología
Spruce Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Updates
Fuente
Spruce Biosciences, Inc.
Editor
Business Wire
1.00
0
08/10/2025
Ciencia
Biotecnología
Farmacéutica
Sanidad
Salud
Mercado laboral
Finanzas
Spruce Biosciences Announces $50.0 Million Private Placement Financing
Fuente
Spruce Biosciences, Inc.
Editor
Business Wire
1.00
0
06/10/2025
Ciencia
Farmacéutica
Ir de compras
Biotecnología
Infancia
Medicina - Varios
Asistencia a la infancia
Higiene alimentaria
Salud
Industria
Spruce Biosciences Receives U.S. FDA Breakthrough Therapy Designation for Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT) in Sanfilippo Syndrome Type B (MPS IIIB)
Fuente
Spruce Biosciences, Inc.
Editor
Business Wire
1.00
0
15/09/2025
Biotecnología
Farmacéutica
Salud
Spruce Biosciences Resumes Trading on the Nasdaq Capital Market
Fuente
Spruce Biosciences, Inc.
Editor
Business Wire
1.00
0
14/08/2025
Biotecnología
Farmacéutica
Salud
Medicina - Varios
Mercado de valores
Spruce Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate Updates
Fuente
Spruce Biosciences, Inc.
Editor
Business Wire
1.00
0
14/08/2025
Spruce Biosciences Announces Integrated Long-Term Clinical Data of Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT) Demonstrating Profound and Durable Efficacy and Safety in Patients with Sanfilippo Syndrome Type B (MPS IIIB)
Fuente
Spruce Biosciences, Inc.
Editor
Business Wire
1.00
0
24/07/2025
Biotecnología
Farmacéutica
Salud
Finanzas
Spruce Biosciences Announces Reverse Stock Split
Fuente
Spruce Biosciences, Inc.
Editor
Business Wire
1.00
0
12/06/2025
Biotecnología
Farmacéutica
Salud
Web y redes sociales
Finanzas
Spruce Biosciences Announces Conditional Nasdaq Approval to Resume Trading on the Nasdaq Capital Market
Fuente
Spruce Biosciences, Inc.
Editor
Business Wire
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0